Hydrogen Sulfide in Pharmacotherapy of Diabetic Kidney Disease | Chapter 9 | Research Developments in Medicine and Medical Science Vol. 3

 Diabetic sort disease (DKD) is currently the chief cause of end-stage renal disease. It accounts for 40% of depression and mortality among the diabetic people despite optimal administration. Its clinical hallmark contains persistent hyperglycemia, hypercreatininemia, uremia, maintained albuminuria, renal hemodynamic changes and elevated blood pressure. Histologically, DKD presents accompanying excessive accumulation and dethroning of extracellular matrix, leading to growth of mesangial matrix, thickening of glomerular vault membrane and tubulointerstitial fibrosis. At the molecular level, expanding evidence suggests that hyperglycemia or high and oxygen mediates renal injury in DKD via diversified molecular mechanisms in the way that induction of oxidative stress, upregulation of renal transforming development factor testing-1 expression, production of supporting-inflammatory cytokines, activation of fibroblasts and renin-angiotensin-aldosterone plan, and depletion of adenosine triphosphate. Moreover, existing medicines only retard the disease progress but do not prevent or reverse it. Therefore, novel modes of pharmacotherapeutic attack are in demand to target supplementary disease mechanisms. A solid body of experimental evidence explains that hydrogen sulfide (H2S), a gas with a memorable notorious label, has recently happened established to acquire important therapeutic possessions that prevent and/or reverses DKD development and progress of DKD by targeting several main molecular pathways, and therefore maybe considered a novel pharmacological agent for DKD situation. The aim of this chapter search out discuss recent exploratory findings on the molecular machines underlying the pharmacotherapeutic effects of H2S against DKD happening and progression, and allure translation from bench to bedside, that could lay the foundation for allure future clinical use.

Author(s) Details:

George J. Dugbartey,
Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, Legon, Accra, Ghana, Department of Surgery, Division of Urology, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada, Matthew Mailing Center for Translational Transplant Studies, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada, Multi-Organ Transplant Program, Western University, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada and Physiology and Pharmacology Unit, Accra College of Medicine, JVX5+FX9, Magnolia St, East Legon, Accra, Ghana.

Please see the link here: https://stm.bookpi.org/RDMMS-V3/article/view/9920